期刊文献+

达克替尼的合成工艺研究 被引量:1

Study on synthetic process to dacomitinib
原文传递
导出
摘要 目的优化达克替尼的合成工艺。方法以2-氨基-4-氟苯甲酸为起始原料,经缩合成环、硝化、卤代、亲核取代、苯环上亲核取代、还原、亲核取代、芬克尔斯坦卤素交换及亲核取代等10步反应制得目标化合物达克替尼。结果目标化合物结构经ESI-MS、^(1)H-NMR、^(13)C-NMR谱确证,总收率为39.2%(以2-氨基-4-氟苯甲酸计),纯度达99.5%(HPLC法)。结论该工艺原料易得、产品纯度高、操作简单、适合工业化生产。 Dacomitinib(1) was an anti-tumor drug, which had a great market prospect in the coming years.A practical and feasible method for the preparation of 1 was described in this paper.Dacomitinib was synthesized from 2-amino-4-fluorobenzoic acid(2) by 10-step synthetic process with an overall yield of 39.2%(based on compound 2-amino-4-fluorobenzoic acid) and purity of 99.5%.The intermediates and target compound were characterized by MS,^(1)H-NMR and ^(13)C-NMR.The synthetic method had the advantages of easy availability of raw materials, simple operation and high product purity, and was suitable for industrial production.
作者 孙浩 郭春 SUN Hao;GUO Chun(School of Pharmaceutical Engineering,Shenyang Pharmaceutical University,Shenyang 110016,China)
出处 《中国药物化学杂志》 CAS CSCD 2022年第5期362-366,共5页 Chinese Journal of Medicinal Chemistry
关键词 达克替尼 2-氨基-4-氟苯甲酸 合成工艺 dacomitinib 2-amino-4-fluorobenzoic acid synthesis process
  • 相关文献

参考文献3

二级参考文献25

  • 1Gonzales AJ, Hook KE, Althaus IW, et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second- generation irreversible pan-erbB receptor tyrosine kinase inhibitor [J]. Mol Cancer Ther, 2008, 7 (7) : 1880-1889.
  • 2Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib [J]. Cancer Res, 2007, 67 (24):11924-11932.
  • 3Fakhoury SA, Lee HT, Reed JE, et al. Preparation of N-(4- phenylamino-quinazolin-6-yl) amides for treating proliferative diseases: US, 20050250761 [P]. 2005-11-10. (CA 2005, 143: 460178).
  • 4Bridges A J, Zhou H, Cody DR, et al. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of4-(3-bromoanilino)-6,7- dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor [J]. J Med Chem, 1996, 39(1): 267-276.
  • 5Himmelsbach F, Langkopf E, Jung B, et al. 4-Amino- quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases: US, 6972288 [P]. 2005-12-06. (CA 2000, 133: 207919).
  • 6Fry DW, Kraker AJ, McMichael A, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase[ J ]. Science, 1994,265(5 175):1 093 -1 095.
  • 7Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804,an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib [ J ]. Cancer Res,2007,67 ( 24 ) : 11 924 - 11 932.
  • 8Ercan D, Zejnullahu K, Yonesaka K,et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor[ J ]. Oncogene,2010,29 ( 16 ) :2 346 - 2 356.
  • 9Rewcastle GW, Denny W A, Bridges AJ, et al. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4- [ ( phenylmethyl ) amino ] -and 4- (phenylamino) quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor [ J ]. J Med Chem, 1995,38 ( 18 ) :3 482 - 3 487.
  • 10Kalous O,Conklin D,Desai AJ,et al. Dacomitinib (PF4)0299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2- amplified breast cancer cell lines resistant to trastuzumab and lapatinib[ J]. Mol Cancer Ther,2012,11(9) :1 978 - 1 987.

共引文献4

同被引文献12

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部